RxDoctor Payments Data

Elissa Townsend

Family · Watertown, NYNPI 1629328422

Payments from drug & device makers

$9,595in general payments, 2019–2025

Across 446 payments — averaging $21.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Regeneron Healthcare Solutions, Inc.$1K
  • Pfizer$867
  • Johnson & Johnson$836
  • Sanofi$790
  • Sun Pharmaceutical Industries Inc.$597
  • plus $4K from 16 others

What the payments were for

  • Food & beverage$9,24096%
  • Education$3564%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,595 in reported general payments places this provider in the 95th percentile of 8,883 family providers in New York.

See all family providers in New York

Medicare billing

Part B allowed, 2024
$136,569
Medicare patients
516
Services billed
4,214

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
SotyktuDeucravacitinib12$76,657
Dupixent PenDupilumab15$54,084
Clobetasol Propionate93$4,705
Pimecrolimus17$3,961
Fluorouracil47$3,230
Ciclopirox31$1,815
Tacrolimus16$1,595
Metronidazole12$1,015
Ketoconazole65$961
Clindamycin Phosphate24$951
Fluticasone Propionate53$917
Nystatin51$609
Triamcinolone Acetonide12$305
Doxycycline Hyclate13$244
Fluconazole14$200

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
E.r. Squibb & Sons, L.L.C.Sotyktu$572$76,65712 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 8,883 family providers in New York.

Other family in Watertown

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →